{"id":"https://openalex.org/W4310089922","doi":"https://doi.org/10.1182/blood-2022-158869","title":"Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)","display_name":"Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310089922","doi":"https://doi.org/10.1182/blood-2022-158869"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-158869","doi":"https://doi.org/10.1182/blood-2022-158869","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-158869","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039574726","display_name":"Sairah Ahmed","orcid":"https://orcid.org/0000-0001-7302-8299","observed_orcids":["https://orcid.org/0000-0001-7302-8299"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sairah Ahmed","raw_affiliation_strings":["1Department of Lymphoma/Myeloma and Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Lymphoma/Myeloma and Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian W. Flinn","raw_affiliation_strings":["2Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063781871","display_name":"Matthew Genyeh Mei","orcid":"https://orcid.org/0000-0002-1109-6955","observed_orcids":["https://orcid.org/0000-0002-1109-6955"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew Mei","raw_affiliation_strings":["3Division of Lymphoma, City of Hope Medical Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Division of Lymphoma, City of Hope Medical Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004821244","display_name":"Peter A. Riedell","orcid":"https://orcid.org/0000-0003-2719-0580","observed_orcids":["https://orcid.org/0000-0003-2719-0580"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter A. Riedell","raw_affiliation_strings":["4Section of Hematology/Oncology, University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Section of Hematology/Oncology, University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053410437","display_name":"Philippe A. Armand","orcid":"https://orcid.org/0000-0001-6098-1603","observed_orcids":["https://orcid.org/0000-0001-6098-1603"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philippe Armand","raw_affiliation_strings":["5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075085884","display_name":"Natalie Sophia Grover","orcid":"https://orcid.org/0000-0002-1346-3157","observed_orcids":["https://orcid.org/0000-0002-1346-3157"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Natalie S. Grover","raw_affiliation_strings":["6Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Renu Balyan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138962","display_name":"Tessa Therapeutic (Singapore)","ror":"https://ror.org/03tk0wy30","country_code":"SG","type":"company","lineage":["https://openalex.org/I4210138962"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"Renu Balyan","raw_affiliation_strings":["7Tessa Therapeutics, Singapore, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Tessa Therapeutics, Singapore, Singapore","institution_ids":["https://openalex.org/I4210138962"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106819398","display_name":"Cliff Ding","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138962","display_name":"Tessa Therapeutic (Singapore)","ror":"https://ror.org/03tk0wy30","country_code":"SG","type":"company","lineage":["https://openalex.org/I4210138962"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"Cliff Ding","raw_affiliation_strings":["7Tessa Therapeutics, Singapore, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Tessa Therapeutics, Singapore, Singapore","institution_ids":["https://openalex.org/I4210138962"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016426367","display_name":"Aung Myo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138962","display_name":"Tessa Therapeutic (Singapore)","ror":"https://ror.org/03tk0wy30","country_code":"SG","type":"company","lineage":["https://openalex.org/I4210138962"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"Aung Myo","raw_affiliation_strings":["7Tessa Therapeutics, Singapore, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Tessa Therapeutics, Singapore, Singapore","institution_ids":["https://openalex.org/I4210138962"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062966348","display_name":"Ivan David Horak","orcid":"https://orcid.org/0009-0003-8726-4016","observed_orcids":["https://orcid.org/0009-0003-8726-4016"]},"institutions":[{"id":"https://openalex.org/I4210138962","display_name":"Tessa Therapeutic (Singapore)","ror":"https://ror.org/03tk0wy30","country_code":"SG","type":"company","lineage":["https://openalex.org/I4210138962"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"Ivan D. Horak","raw_affiliation_strings":["7Tessa Therapeutics, Singapore, Singapore"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Tessa Therapeutics, Singapore, Singapore","institution_ids":["https://openalex.org/I4210138962"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021029688","display_name":"Helen Elisabeth Heslop","orcid":"https://orcid.org/0000-0001-7049-7698","observed_orcids":["https://orcid.org/0000-0001-7049-7698"]},"institutions":[{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Helen E. Heslop","raw_affiliation_strings":["8Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX","institution_ids":["https://openalex.org/I181547552"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":1.6582,"has_fulltext":false,"cited_by_count":20,"citation_normalized_percentile":{"value":0.8657955,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":96,"max":98},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"7496","last_page":"7497"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/car-t-cell-persistence","display_name":"CAR T cell persistence","score":0.6349999904632568},{"id":"https://openalex.org/keywords/cytokine-profiling","display_name":"cytokine profiling","score":0.671999990940094},{"id":"https://openalex.org/keywords/circulating-tumor-dna","display_name":"circulating tumor DNA","score":0.9359999895095825},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.6140000224113464},{"id":"https://openalex.org/keywords/pd-1-expression","display_name":"PD-1 expression","score":0.5019999742507935},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.6579999923706055},{"id":"https://openalex.org/keywords/pd-1-pd-l1-blockade","display_name":"PD-1/PD-L1 blockade","score":0.6159999966621399},{"id":"https://openalex.org/keywords/brentuximab-vedotin","display_name":"brentuximab vedotin","score":0.824999988079071},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.5690000057220459},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.3499999940395355}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6353501677513123},{"id":"https://openalex.org/C2776800370","wikidata":"https://www.wikidata.org/wiki/Q5172864","display_name":"Correlative","level":2,"score":0.5652279853820801},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.553741455078125},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5363904237747192},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.47209328413009644},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.46742910146713257},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45539987087249756},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.13770654797554016},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.0},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0},{"id":"https://openalex.org/C41895202","wikidata":"https://www.wikidata.org/wiki/Q8162","display_name":"Linguistics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-158869","doi":"https://doi.org/10.1182/blood-2022-158869","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-158869","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3214626906","https://openalex.org/W4417002055","https://openalex.org/W2196039424","https://openalex.org/W2910288910","https://openalex.org/W2513177163","https://openalex.org/W2901937382","https://openalex.org/W4281868964","https://openalex.org/W4310106518","https://openalex.org/W4417019939","https://openalex.org/W4380084558"],"abstract_inverted_index":{"Introduction":[0],"Early":[1],"results":[2],"from":[3,57],"the":[4,58,107,171,224,286,347,356,363,405,504],"Pilot":[5,59,225],"segment":[6,97,226,506],"of":[7,12,34,83,98,155,186,190,211,237,274,293,331,365,378,404,428,473,497,507],"a":[8,26,64,133,257,425,445],"Phase":[9,65,509],"2":[10,66,510],"trial":[11],"autologous":[13,191],"CD30.CAR-T":[14,35,141,161,166,180,250,259,263,297,313,358,441,455,482,498],"in":[15,36,204,223,278,315,390,399,432,450,475,503],"patients":[16,37,72,137,172,216,221,246,255,280],"with":[17,38,75,104,140,150,249,269,281,291,302,326,375,460,470],"relapsed/refractory":[18],"(r/r)":[19],"classical":[20],"Hodgkin":[21],"lymphoma":[22,127],"(cHL)":[23],"(NCT#04268706)":[24],"demonstrated":[25],"favorable":[27],"safety":[28,105,463,493],"profile":[29],"and":[30,53,89,110,148,188,201,206,219,253,310,341,367,383,396,410,420,443,465,487,494],"excellent":[31,467],"anti-tumor":[32,468],"responses":[33],"heavily":[39,476],"pretreated":[40,477],"r/r":[41,478],"cHL":[42,76,479],"(Ahmed":[43],"et":[44,129,435],"al.,":[45,130,436],"2021).":[46],"We":[47],"report":[48],"here":[49],"updated":[50],"clinical":[51],"data":[52],"exploratory":[54,495],"biomarker":[55],"analysis":[56],"segment.":[60],"Methods":[61],"This":[62],"is":[63,168],"single":[67,251,264],"arm,":[68],"multi-center":[69],"study,":[70],"enrolling":[71],"(12-75":[73],"years)":[74],"progression":[77,174],"after":[78,143,175,262,285,322,355,394,414,448,489],"at":[79,319,362],"least":[80],"3":[81],"lines":[82],"therapy,":[84],"including":[85],"chemotherapy,":[86],"brentuximab":[87],"vedotin,":[88],"anti-programmed":[90],"cell":[91],"death":[92],"(PD)-1":[93],"antibodies.":[94],"The":[95,136,234,481,491],"pilot":[96],"this":[99,508],"study":[100],"has":[101],"fully":[102],"enrolled":[103,222],"as":[106,115,132],"primary":[108],"endpoint":[109],"overall":[111],"response":[112,177,271,283,340,430],"rate":[113,273],"(ORR)":[114],"assessed":[116],"centrally":[117],"according":[118],"to":[119,157,178],"Lugano":[120],"Classification":[121],"Revised":[122],"Response":[123],"System":[124],"for":[125],"malignant":[126],"(Cheson":[128],"2014)":[131],"secondary":[134],"endpoint.":[135],"were":[138,217,247,369],"treated":[139,248],"cells,":[142],"lymphodepletion":[144,415],"chemotherapy":[145],"using":[146],"bendamustine":[147],"fludarabine,":[149],"an":[151,372,471],"allowable":[152],"dose":[153],"range":[154],"2.0":[156],"2.7":[158],"\u00d7":[159],"108":[160],"cells":[162,314,483],"per":[163],"m2.":[164],"Second":[165],"infusion":[167,265,288,325,398,442],"allowed":[169],"if":[170],"show":[173],"initial":[176],"first":[179,323,357,395],"infusion.":[181,260,359,490],"Exploratory":[182],"objectives":[183],"include":[184],"assessment":[185,284,431],"expansion":[187,486],"persistence":[189,488],"CD30.CAR-T,":[192],"cytokine":[193],"profiling,":[194],"immunological":[195],"parameters,":[196],"circulating":[197],"tumor":[198,207],"DNA":[199],"(ctDNA),":[200],"other":[202],"biomarkers":[203,496],"blood":[205,317],"tissue.":[208],"Results":[209],"As":[210],"22":[212],"July":[213],"2022,":[214],"17":[215],"screened":[218],"15":[220,245],"(median":[227],"age:":[228],"35":[229],"years":[230],"[21-57],":[231],"66.7%":[232],"male).":[233],"median":[235,327],"number":[236],"prior":[238],"therapies":[239],"was":[240,266,289,299,335,392,412,438,457],"6":[241],"(range:":[242],"3-18).":[243],"All":[244],"infusion,":[252],"7":[254,320],"received":[256],"second":[258,287],"ORR":[261,277,472],"73.3%":[267,474],"(n=11)":[268],"complete":[270],"(CR)":[272],"60%":[275,294],"(n=9).":[276],"5":[279],"available":[282],"100%,":[290],"CR":[292],"(n=":[295],"3).":[296],"treatment":[298,449],"well":[300,458],"tolerated":[301,459],"one":[303],"grade":[304],"1":[305],"Cytokine":[306],"Release":[307],"Syndrome":[308],"(CRS)":[309],"no":[311,336,461],"neurotoxicity.":[312],"peripheral":[316],"peaked":[318],"days":[321,354],"CAR-T":[324],"Cmax":[328],"(peak":[329],"exposure)":[330],"6964.7":[332],"copies/\u00b5g":[333],"DNA.There":[334],"correlation":[337],"observed":[338],"between":[339,381],"Cmax,":[342],"or":[343],"AUC":[344],"(area":[345],"under":[346],"curve)":[348],"0-42":[349],"days,":[350,352],"0-90":[351],"0-180":[353],"Biopsies":[360],"obtained":[361],"time":[364],"screening":[366],"relapse":[368],"reviewed":[370],"by":[371],"independent":[373],"pathologist":[374],"100%":[376],"concordance":[377],"CD30":[379],"positivity":[380],"local":[382],"central":[384],"testing.":[385],"HAMA":[386],"(Human":[387],"Anti-Mouse":[388],"Antibody)":[389],"serum":[391],"negative":[393],"secondCD30.CAR-T":[397],"all":[400],"patients.":[401,452,480],"An":[402],"increase":[403],"homeostatic":[406],"cytokines":[407],"interleukin":[408],"(IL)-7":[409],"IL-15":[411],"detected":[413],"chemotherapy.":[416],"Serum":[417],"CCL17":[418],"(Thymus":[419],"Activation":[421],"Regulated":[422],"Chemokine;":[423],"TARC),":[424],"predictive":[426],"marker":[427],"early":[429],"HL":[433],"(Guidetti":[434],"2017)":[437],"elevated":[439],"before":[440],"had":[444],"dramatic":[446],"decrease":[447],"responding":[451],"Conclusions":[453],"Overall,":[454],"therapy":[456],"unexpected":[462],"signal":[464],"showed":[466,484],"efficacy":[469],"good":[485],"efficacy,":[492],"will":[499],"be":[500],"further":[501],"evaluated":[502],"Pivotal":[505],"study.":[511]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":7}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-11-30T00:00:00"}